And it could impact digital health
As Americans juggle cash-pay care and high-deductible insurance, companies like Aidoc, Datavant, and Prosper AI are testing whether tech can ease the pressure.
Plus, a review of Prenuvo’s enhanced screening
As startups chase hot markets like GLP-1s and testosterone, the Trump Administration continues to push on wellness - and not always with the evidence to back it up. Deals are finally ramping up (and why). Plus a “Four Questions with” interview with digital health OG Halle Tecco!
Why “Power Law” venture math is more challenging for value-based care, versus fee-for-service, and whether AI will make a difference
"Tectonic Shifts" are happening as inflation, drug pricing battles, and cash-pay healthcare are colliding to redefine the industry’s next era.
Per our anonymous survey, this is what clinicians take & why
Reimbursement is patchy, but a big business will be created here as more patients gravitate to messaging
Why funding has slowed, where gaps remain, and what the next wave of innovation could look like.
‘One Big, Beautiful Bill’ did a solid for direct primary care, longevity and telehealth, which may open up the employer channel in a big way for some digital health companies
7wire shared their thesis and market map with us that it created for its own LPs
How healthcare founders should take lessons from teams navigating unpredictable events
Between Function Health, Lifeforce and Superpower, this space is on fire
Some digital health companies are getting more targeted with their approach
And it’s rapidly evolving in real time!
Let’s get real about the alliance between U.S. health care and employment
I teamed up with two health policy experts to explore the bull and bear case.
The company closed up shop abruptly this week.
Important new data is out today indicating that might be the case — and for the very reason you might expect!
Health care is a tough market, but there are invariably going to be big opportunities, according to Maveron's Jason Stoffer
Build for the needs of a community, not a single condition
RCM, transparency tools, HSA/FSAs and more
Not all companies (or hormones) are created equal
In this market, we're undervaluing and underestimating brick and mortar
The valuation may seem crazy, but it's actually not...
